beta

You're viewing our new website - find out more

Publication - Report

Review of Access to New Medicines

Published: 14 Dec 2016
Part of:
Health and social care
ISBN:
9781786526939

An independent review to assess the impact of the new approach introduced in 2014 by Scottish Medicines Consortium (SMC).

60 page PDF

655.3kB

60 page PDF

655.3kB

Contents
Review of Access to New Medicines
Appendix 2: Task & Finish Group Definitions for end-of-life, orphan and ultra-orphan medicines

60 page PDF

655.3kB

Appendix 2: Task & Finish Group Definitions for end-of-life, orphan and ultra-orphan medicines

Task and Finish Group Definitions

End-of-Life Medicine:

"A medicine used to treat a condition at a stage that usually leads to death within 3 years with currently available treatments."

Orphan Medicine:

"A medicine with European Medicines Agency ( EMA) designated orphan status ( i.e. conditions affecting fewer than 2,500 people in a population of 5 million) or a medicine to treat an equivalent size of population irrespective of whether it has designated orphan status."

Ultra-Orphan Medicine:

"A medicine used to treat a condition with a prevalence of 1 in 50,000 or less (or around 100 people in Scotland)".


Contact